Urothelial Cancer
Clinical research in unresectable locally advanced urothelial cancer and metastatic urothelial cancer, with attention to disease control after first-line treatment and maintenance strategies.
- Maintenance immunotherapy
- Progression-free survival
- Advanced urothelial disease
The sponsor’s activity in this area centers on treatment approaches for patients whose disease remains active beyond initial systemic therapy.
Muscle-Invasive Bladder Cancer
Research focused on muscle-invasive bladder cancer and muscle-invasive bladder cancer (MIBC), including strategies aimed at preserving the bladder while improving tumor response.
- Bladder preservation
- Pathological complete response
- Local tumor control
Trials in this field address treatment options for patients with localized aggressive bladder cancer requiring multimodal management.
Neoadjuvant Treatment
Investigation of neoadjuvant therapy for patients with cisplatin-ineligible muscle-invasive bladder cancer, with interest in improving surgical outcomes before definitive local treatment.
- Pathological downstaging
- Preoperative systemic therapy
- FGFR gene alterations
This area reflects a focus on biomarker-informed treatment selection in bladder cancer.
Radiotherapy and Immunotherapy
Clinical interest in combining radiotherapy with atezolizumab for patients with muscle-invasive bladder cancer treated with bladder-sparing intent.
- Concurrent treatment
- Immune checkpoint inhibition
- Bladder-sparing therapy
Research in this domain examines tumor response in the setting of combined local and systemic treatment.
